1250998-26-5

Basic information

• Product Name: Ethyl 2-Chloroimidazo[1,5-A]Pyrimidine-8-Carboxylate
• Synonyms: Ethyl 2-Chloroimidazo[1,5-A]Pyrimidine-8-Carboxylate;Ethyl 2-Chloroimidazo[1,5-A]Pyrimidine-8-Carboxylate(WX130017)
• CAS NO: 1250998-26-5
• Molecular Formula: C9H8ClN3O2
• Molecular Weight: 225.63172
• Mol File: 1250998-26-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 2-Chloroimidazo[1,5-A]Pyrimidine-8-Carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-Chloroimidazo[1,5-A]Pyrimidine-8-Carboxylate(1250998-26-5)
• EPA Substance Registry System: Ethyl 2-Chloroimidazo[1,5-A]Pyrimidine-8-Carboxylate(1250998-26-5)

Safety Data

• Hazardous Substances Data: 1250998-26-5(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 222292-71-9 2-oxo-1,2-dihydro-imidazo[1,5-a]pyrimidine-8-carboxylic acid amide 
• 222292-69-5 ethyl 2-oxo-1,2-dihydroimidazo[1,5-a]pyrimidine-8-carboxylate 
• 21190-16-9 5-amino-1H-imidazole-4-carboxylic acid ethyl ester 

Downstream Products

• 1431654-63-5 ethyl 2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxylate 
• 1431654-64-6 2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxylic acid 
• 1431647-28-7 N-(pyridin-3-yl)-2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxamide 
• 1431654-65-7 2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-amine 
• 1431647-32-3 N-(2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-yl)picolinamide 

Relevant articles and documents

Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma

Harboring MYD88 L265P mutation triggers tumors growth through the activation of NF-κB by interleukin-1 receptor associated kinase 4 (IRAK4) in diffuse large B-cell lymphoma (DLBCL), highlighting IRAK4 as a therapeutic target for tumors driven by aberrant MYD88 signaling. Herein, we report the design, synthesis, and structure?activity relationships of imidazo[1,2-b]pyridazines as potent IRAK4 inhibitors. The representative compound 5 exhibited excellent IRAK4 potency (IRAK4 IC50 = 1.3 nM) and favorable kinase selectivity profile. It demonstrated cellular selectivity for activated B cell–like (ABC) subtype DLBCL with MYD88 L265P mutation in cytotoxicity assay. The kinase inhibitory efficiency of compound 5 was further validated by Western blot analysis of phosphorylation of IRAK4 and downstream signaling in OCI-LY10 and TMD8 cells. Besides, combination of compound 5 and BTK inhibitor ibrutinib synergistically reduced the viability of TMD8 cells. These results indicated that compound 5 could be a promising IRAK4 inhibitor for the treatment of mutant MYD88 DLBCL.

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin- modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.